You just read:

KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial

News provided by

Amgen

Dec 11, 2017, 16:00 ET